| Name | Title | Contact Details |
|---|---|---|
Timothy Meigs |
Chief Intellectual Property Counsel | Profile |
Christopher Matton |
General Counsel | Profile |
Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.
Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio`s optimized plasmid design and delivery technology have been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio`s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, GBM, and prostate cancer, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and COVID-19. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Inovio also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors.
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
Better chemistry committed to the world`s biggest problems